How Trump’s reshoring EO affects plans to build or expand a domestic drug manufacturing facility
By EsqSocial Corporation 08/05/25
Investments in new (“greenfield”) or expanded (“brownfield,” “retrofit”) domestic manufacturing capabilities require years of strategic planning and capital expenditure. Even with the announcement of near-term incentives and reduced regulatory complexities for domestic manufacturing in the Trump administration’s May 5 Executive Order aiming to promote American-made prescription drugs (“Reshoring Manufacturing EO”), companies deciding whether to reshore manufacturing need to consider longer-term...
By: Hogan Lovells